Clinicopathological Features of Hepatocellular Carcinoma with Metabolic Risk Factors

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview[J]. Int J Cancer. 2021;149:778–789. doi:10.1002/ijc.33588
   Web of Science ®Google Scholar
• Eslam M, Newsome PN, Anstee QM, et al. A new definition for metabolic dysfunctionassociated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Chen VI, Yeh ML, Yang JD. Effects of cirrhosis and diagnosis scenario in metabolic-associated fatty liver disease-related hepatocellular carcinoma. Hepatol Commun. 2020;5(1):122–132. doi:10.1002/hep4.1606
   PubMed Web of Science ®Google Scholar
• Guo F, Estévez-Vázquez O, Benedé-Ubieto R, et al. A Shortcut from Metabolic-Associated Fatty Liver Disease(MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. Cancers. 2022;14(1):192. doi:10.3390/cancers14010192
   Web of Science ®Google Scholar
• Xie XC, Zheng MY, Guo WB, et al. Correlation analysis of metabolic characteristics and the risk of metabolic‑associated fatty liver disease-related hepatocellular carcinoma. Sci Rep. 2022;12(1):13969. doi:10.1038/s41598-022-18197-6
   PubMed Web of Science ®Google Scholar
• Sun L, Jia-min C, Yang K, et al. Cytomegalovirus cell tropism and clinicopathological characteristics in gastrointestinal tract of patients with HIV/ AIDS. Diagn Pathol. 2022;17:9. doi:10.1186/s13000-022-01193-9
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi:10.1002/hep.20701
   PubMed Web of Science ®Google Scholar
• Won Bae SD, George J, Qiao L. From MAFLD to hepatocellular carcinoma and everything in between. Chin Med J. 2022;135(5):547–556. doi:10.1097/CM9.0000000000002089
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723–1730. doi:10.1002/hep.28123
   PubMed Web of Science ®Google Scholar
• Hörist-Kollmann S, Strametz-Juranek J. Female dietary patterns and the pathogenesis of NAFLD. Gend Genome. 2018;2:49–55. doi:10.1177/2470289718787091
   Google Scholar
• Reeves HL, Zaki MY, Day CP. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Dig Dis Sci. 2016;61(5):1234–1245. doi:10.1007/s10620-016-4085-6
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Karadag Soylu N. Update on hepatocellular carcinoma: a brief review from pathologist standpoint. J Gastrointest Cancer. 2020;51(4):1176–1186. doi:10.1007/s12029-020-00499-5
   PubMed Web of Science ®Google Scholar
• Torbenson MS, Iol N, Park YN, et al. Hepatocellular carcinoma. WHO Classification of Tumours Editorial Board, editor. Digestive System Tumours. WHO Classification of Tumours Series. 5th. Lyon: International Agency for Research on Cancer; 2019. 230.
   Google Scholar
• Yeh MM, Liu Y, Torbenson M. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. Hum Pathol. 2015;46:1769–1775. doi:10.1016/j.humpath.2015.07.018
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Saitoh S, Kinowaki K, et al. Clinicopathological assessment of steatohepatitic hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2022;46(8):101799. doi:10.1016/j.clinre.2021.101799
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Nakagawa H, Enooku K, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut. 2018;67(8):1493–1504. doi:10.1136/gutjnl-2017-315193
   PubMed Web of Science ®Google Scholar
• Mostafa M, Abdelkader A, Evans JJ, et al. Fatty liver disease: a practical approach. Arch Pathol Lab Med. 2020;144:62–70. doi:10.5858/arpa.2019-0341-RA
   PubMed Web of Science ®Google Scholar
• Vyas M, Zhang X. Hepatocellular Carcinoma: role of Pathology in the Era of Precision Medicine. Clin Liver Dis. 2020;24(4):591–610. doi:10.1016/j.cld.2020.07.010
   PubMed Web of Science ®Google Scholar
• Feng J, Zhu R, Chang C, et al. CK19 and glypican 3 expression profiling in the prognostic indication for patients with HCC after surgical resection. PLoS One. 2016;11(3):e0151501. doi:10.1371/journal.pone.0151501
   PubMed Web of Science ®Google Scholar
• Chrostek L, Supronowicz L, Panasiuk A, et al. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Clin Exp Med. 2014;14:417–421. doi:10.1007/s10238-013-0262-5
   PubMed Web of Science ®Google Scholar
• Konishi K, Miyake T, Furukawa S, et al. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor. Atherosclerosis. 2020;299:32–37. doi:10.1016/j.atherosclerosis.2020.02.026
   PubMed Web of Science ®Google Scholar
• Rehberger Likozar A, Zavrtanik M, Šebeštjen M. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. Ann Med. 2020;52(5):162–177. doi:10.1080/07853890.2020.1775287
   PubMed Web of Science ®Google Scholar
• Wu T, Ye J, Shao C, et al. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease. Front Endocrinol (Lausanne). 2021;12:691556. doi:10.3389/fendo.2021.691556
   PubMed Web of Science ®Google Scholar
• Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta. 2013;1830:2481–2495. doi:10.1016/j.bbagen.2012.11.008
   PubMed Web of Science ®Google Scholar
• Carr BI, Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology. 2016;90:215–220. doi:10.1159/000444394
   PubMed Web of Science ®Google Scholar
• Hayashi H, Beppu T, Shirabe K, et al. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol. 2014;20:2595–2605. doi:10.3748/wjg.v20.i10.2595
   PubMed Web of Science ®Google Scholar
• Carr BI, Guerra V. Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase. Oncology. 2013;85:153–159. doi:10.1159/000354416
   PubMed Web of Science ®Google Scholar
• Pang Q, Liu S, Wang L, et al. The Significance of Platelet-Albumin-Bilirubin (PALBI) Grade in Hepatocellular Carcinoma Patients Stratified According to Platelet Count. Cancer Manag Res. 2020;12:12811–12822. doi:10.2147/CMAR.S277013
   PubMed Web of Science ®Google Scholar
• Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011–1018. doi:10.1038/modpathol.2008.85
   PubMed Web of Science ®Google Scholar
• Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827–838. doi:10.1002/hep.28368
   PubMed Web of Science ®Google Scholar
• Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14:124–131. doi:10.1016/j.cgh.2015.07.019
   PubMed Web of Science ®Google Scholar
• Tobari M, Hashimoto E, Taniai M, et al. The characteristics and risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis. J Gastroenterol Hepatol. 2020;35(5):862–869. doi:10.1111/jgh.14867
   PubMed Web of Science ®Google Scholar